We are live on ! Find out more
MCM

Marathon Capital Management Portfolio holdings

AUM $445M
1-Year Est. Return 26.09%
This Fund
S&P 500
This Quarter Est. Return
+9.25%
1 Year Est. Return
+26.09%
3 Year Est. Return
+49.93%
5 Year Est. Return
+48.4%
10 Year Est. Return
+349.58%
AUM
$294M
AUM Growth
+$46.1M
Cap. Flow
+$24.4M
Cap. Flow %
8.31%
Top 10 Hldgs %
61.87%
Holding
154
New
41
Increased
56
Reduced
28
Closed
12

Top Buys

Rank Stock Value
1
BRK.B icon
Berkshire Hathaway Class B
BRK.B
+$1.93M
2
CVX icon
Chevron
CVX
+$1.85M
3
BMY icon
Bristol-Myers Squibb
BMY
+$1.78M
4
AAPL icon
Apple
AAPL
+$1.72M
5
ABBV icon
AbbVie
ABBV
+$1.43M

Sector Composition

Rank Sector Weight
1 Financials 51.87%
2 Technology 15.43%
3 Healthcare 7.74%
4 Industrials 7.23%
5 Energy 6.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
TROW icon
1
T. Rowe Price
TROW
$25.1B
$139M 47.23%
1,139,982
-40,209
-3% -$4.75M
ENPH icon
2
Enphase Energy
ENPH
$5.48B
$8.83M 3%
338,065
+1,790
+0.5% +$40.7K
AAPL icon
3
Apple
AAPL
$4.9T
$8.11M 2.76%
110,440
+26,724
+32% +$1.72M
GLW icon
4
Corning
GLW
$133B
$4.46M 1.52%
153,356
+37,544
+32% +$1.09M
JNJ icon
5
Johnson & Johnson
JNJ
$609B
$4.24M 1.44%
29,045
+6,640
+30% +$901K
MSFT icon
6
Microsoft
MSFT
$2.93T
$3.77M 1.28%
23,892
-1,648
-6% -$242K
GSK icon
7
GSK
GSK
$104B
$3.55M 1.21%
60,506
+3,708
+7% +$206K
QCOM icon
8
Qualcomm
QCOM
$181B
$3.38M 1.15%
38,330
-8,517
-18% -$713K
CVS icon
9
CVS Health
CVS
$137B
$3.36M 1.14%
45,269
+325
+0.7% +$22.8K
ABB
10
DELISTED
ABB Ltd
ABB
$3.35M 1.14%
138,987
+17,950
+15% +$385K
BMY icon
11
Bristol-Myers Squibb
BMY
$124B
$3.34M 1.14%
52,034
+31,057
+148% +$1.78M
MDC
12
DELISTED
M.D.C. Holdings, Inc.
MDC
$3.33M 1.13%
94,161
+33,286
+55% +$1.25M
ACA icon
13
Arcosa
ACA
$7.12B
$3.23M 1.1%
72,495
AL
14
DELISTED
Air Lease Corp
AL
$2.73M 0.93%
57,575
-3,200
-5% -$144K
WAAS
15
DELISTED
AquaVenture Holdings Limited
WAAS
$2.72M 0.93%
100,370
+15,550
+18% +$330K
USB icon
16
US Bancorp
USB
$98.4B
$2.68M 0.91%
45,135
+19,700
+77% +$1.14M
TRGP icon
17
Targa Resources
TRGP
$60.7B
$2.65M 0.9%
64,875
+1,775
+3% +$68.9K
BRK.B icon
18
Berkshire Hathaway Class B
BRK.B
$1.06T
$2.56M 0.87%
11,328
+8,884
+364% +$1.93M
NOK icon
19
Nokia
NOK
$56.5B
$2.51M 0.85%
676,250
+201,375
+42% +$792K
PSX icon
20
Phillips 66
PSX
$82.9B
$2.46M 0.84%
22,082
+10,195
+86% +$1.15M
KN icon
21
Knowles
KN
$3.01B
$2.46M 0.84%
116,291
-3,725
-3% -$80K
ABBV icon
22
AbbVie
ABBV
$450B
$2.31M 0.79%
26,101
+17,185
+193% +$1.43M
ZYME icon
23
Zymeworks
ZYME
$1.78B
$2.24M 0.76%
49,310
-3,125
-6% -$114K
MET icon
24
MetLife
MET
$60.5B
$2.09M 0.71%
41,030
+200
+0.5% +$9.65K
BP icon
25
BP
BP
$108B
$2.06M 0.7%
54,573
-666
-1% -$25.3K

Similar funds

Marathon Capital Management's Q4 2019 Portfolio in Review

As of Q4 2019, Marathon Capital Management held 154 positions worth $294M, up 19% from $248M the previous quarter. Its ten largest holdings account for 62% of the portfolio.

Marathon Capital Management deployed $24.4M of net new capital in Q4 2019, opening 41 new positions and adding to 56 existing holdings. Its largest new stake was Chevron: 15,672 shares worth $1.89M.

By sector, the portfolio is most concentrated in Financials at 52% of assets, down from 57% a quarter earlier, followed by Technology and Healthcare.

On the sell side, the largest reduction was T. Rowe Price, an estimated $4.75M trimmed.

  • Marathon Capital Management's largest Q4 2019 buy was Chevron: 15,672 shares worth $1.89M.
  • Marathon Capital Management added most to Berkshire Hathaway Class B in Q4 2019, an estimated $1.93M increase.
  • Marathon Capital Management's biggest Q4 2019 reduction was T. Rowe Price, cutting an estimated $4.75M.
  • Marathon Capital Management fully exited Sprott Physical Gold and Silver Trust in Q4 2019, selling an estimated $2.69M.
  • Marathon Capital Management's ten largest holdings make up 62% of its $294M portfolio in Q4 2019.
  • Marathon Capital Management opened 41 new positions and closed 12 in Q4 2019.
  • Marathon Capital Management's portfolio value rose 19% quarter-over-quarter to $294M.

Based on Marathon Capital Management's 13F filing for Q4 2019, filed 14 Feb 2020.